DrugPatentWatch Database Preview
saxenda Drug Profile
Which patents cover Saxenda, and what generic alternatives are available?
Saxenda is a drug marketed by Novo and is included in one NDA. There are twenty-two patents protecting this drug.
This drug has two hundred and eighty patent family members in twenty-nine countries.
The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the liraglutide recombinant profile page.
Summary for saxenda
| International Patents: | 280 |
| US Patents: | 22 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 13 |
| Clinical Trials: | 23 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for saxenda |
| Drug Sales Revenues: | Drug sales revenues for saxenda |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for saxenda |
| DailyMed Link: | saxenda at DailyMed |
Recent Clinical Trials for saxenda
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Federico II University | Phase 4 |
| Texas Tech University | N/A |
| Rebecca Ashare | Phase 2 |
Recent Litigation for saxenda
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. | 2017-03-03 |
| SMITH v. NOVO NORDISK INC. | 2016-08-08 |
Pharmacology for saxenda
| Drug Class | GLP-1 Receptor Agonist |
| Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
US Patents and Regulatory Information for saxenda
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for saxenda
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | Start Trial | Start Trial |
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for saxenda
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 1843809 | Start Trial |
| Japan | 2013154219 | Start Trial |
| Canada | 2491356 | Start Trial |
| European Patent Office | 0929576 | Start Trial |
| Australia | 2002316811 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for saxenda
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2209800 | 122014000114 | Germany | Start Trial | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| 2597103 | 2017/015 | Ireland | Start Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912 |
| 2209800 | C300698 | Netherlands | Start Trial | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
| 0944648 | 09C0054 | France | Start Trial | PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630 |
| 0944648 | SPC034/2009 | Ireland | Start Trial | SPC034/2009: 20101001, EXPIRES: 20220821 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
